MANCHESTER, England, Aug. 13, 2024 /PRNewswire/ -- Smartkem (Nasdaq: SMTK), a company that has the potential to power the next generation of displays using its disruptive organic thin-film transistors (OTFTs), today provides a business update and reports financial results for the three and six months ended June 30, 2024.
Recent Business Highlights
During Q1 and Q2 2024, Smartkem:
- Announced that it had uplisted to The Nasdaq Stock Market.
- Commenced a project with RiTdisplay, with whom it entered into a joint development agreement in 2021, to develop the world's first commercially ready active-matrix OLED (AMOLED) display using OTFT technology. This new project is funded by Innovate UK (part of UK Research and Innovation (UKRI)), as part of the Taiwan-UK Research & Development Collaboration.
- Entered into a technology collaboration agreement with the Industrial Technology Research Institute (ITRI) in Taiwan.
- Began collaborating with FlexiIC to develop low-cost, rapid turnaround custom circuits using OTFT technology.
- Entered into a joint development agreement with Tianma to develop OTFT biosensors.
- Joined the Hi-Accµracy Project to develop active-matrix printed Q-LED displays.
- Exhibited and gave company presentations at key trade industry conferences including Touch Taiwan 2024 and Display Week 2024 in San Jose, where CEO Ian Jenks gave a keynote speech at the DSCC / SID Business Conference.
- Cash and cash equivalents as of June 30, 2024, were $4.4 million compared to $8.8 million as of December 31, 2023.
- Operating expenses for the three months ended June 30, 2024, were $3.0 million compared $2.5 million for the same period of 2023.
- Revenues for the three months ended June 30, 2024, were $40.0 thousand compared to $8.0 thousand for the same period of 2023.
- In May 2024, Smartkem received approval to list its common stock on the Capital Market tier of The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "SMTK". Trading on Nasdaq commenced with the open of trading on Friday, May 31, 2024.
Smartkem Chairman and CEO, Ian Jenks, comments,
"The most exciting 2024 milestone for the company so far is the recent announcement of our uplist to Nasdaq. We are proud to now be trading on the world's premier technology stock exchange and believe that it will result in increased marketability and liquidity."
"In the first half of 2024, we delivered against our commitment to increase our marketing efforts and participation in the major global technology conferences, and, crucially, believe we have continued to demonstrate company success and viability through the delivery of our robust three-pillared commercialization strategy that has remained consistent: continuous improvement of our proprietary materials, the development of electronic design automation (EDA) tools, and access to foundry services."
"We are committed to continuous improvement of our best-in-class materials, supported by ongoing confidence from both the industry and investor communities. We intend to deploy EDA tools to the market through our partnership with FlexiIC, enabling customers to rapidly develop circuitry at low cost for new applications in sensors, internet-of-things (IOT) or other applications. We also intend to grant our customers access to foundry services and have entered into a technology transfer agreement with the Industrial Technology Research Institute (ITRI) in Taiwan to enable product prototyping on its Gen2.5 line for customers as they approach product commercialization.
"We remain confident that our continued efforts to pursue our three-pillared strategy will lead to commercialization and the sale of our materials to both foundry services and to our customers who have transferred our technology to their own fabrication lines."
Q2 2024 Results:
Revenue and Cost of revenue
Smartkem had revenue of $40.0 thousand and cost of revenue $32.0 thousand in the three months ended June 30, 2024. Smartkem had revenue of $8.0 thousand and cost of revenue of $6.0 thousand in the same period of 2023. Both revenues and related cost of revenue for the three months ended June 30, 2024, and 2023 are a result of sales of OTFT backplanes and TRUFLEX® materials for customer assessment and development purposes.
Other operating income
Other operating income was $0.2 million in the three months ended June 30, 2024, compared to $0.2 million in the same period of 2023. The primary source of the income is related to a research grant and research and development tax credits.
Operating expenses
Operating expenses were $3.0 million for the three months ended June 30, 2024, compared to $2.5 million in the same period of 2023, an increase of $0.5 million.
Research and development expenses are incurred for the development of TRUFLEX® inks to make OTFT circuits and consist primarily of payroll and technical development costs. The research and development expenses represent 38.4% and 49.5% of the total operating expenses for the three months ended June 30, 2024, and 2023, respectively. Research and development expenses decreased $98 thousand for the three months ended June 30, 2024, compared to the same period for the prior year. This decrease is primarily related to lower personnel expenses due to a reduction in force in 2023 and additional personnel resignations in 2024, offset in part by higher technical service costs.
Selling, general and administrative expenses consist primarily of payroll and professional services such as accounting, legal services and investor relations. These expenses represent 61.0% and 52.2% of our total operating expenses for the three months ended June 30, 2024, and 2023, respectively. Selling, general and administrative expenses increased by $0.5 million for the three months ended June 30, 2024, compared to the same period for the prior year. This increase was primarily a result of an increase in personnel expenses related to salary increases and bonus payouts and professional service fees related to the NASDAQ uplisting.
Non-Operating income /Expense
We recorded a loss of $81 thousand related to the valuation of the warrant liability for the three months ended June 30, 2024, compared to a gain of $3 thousand for the same period in 2023. We had transaction costs of $0.2 million related to a private placement financing for the three months ended June 30, 2023, with no similar costs in the same period of 2024. We recorded a loss on foreign currency transactions of $0.2 million for the three months ended June 30, 2024, compared to gain of $0.5 million in the same period on 2023.
Cash Flow from Operating Activities
Net cash used in operating activities was $4.4 million for the six months ended June 30, 2024, compared to $3.1 million for the six months ended June 30, 2023, an increase of $1.5 million. The increase is primarily related to the timing of payments made to vendors and the payout of bonuses.
Smartkem's Nasdaq information can be found on the Nasdaq website: https://www.nasdaq.com/market-activity/stocks/smtk
| SMARTKEM, INC. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (Unaudited) | ||||||
| (in thousands, except number of shares and per share data) | ||||||
| June 30, | December 31, | |||||
| 2024 | 2023 | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 4,351 | $ | 8,836 | ||
| Accounts receivable | - | 268 | ||||
| Research and development tax credit receivable | 967 | 610 | ||||
| Prepaid expenses and other current assets | 1,186 | 811 | ||||
| Total current assets | 6,504 | 10,525 | ||||
| Property, plant and equipment, net | 327 | 455 | ||||
| Right-of-use assets, net | 226 | 285 | ||||
| Other assets, non-current | 6 | 7 | ||||
| Total assets | $ | 7,063 | $ | 11,272 | ||
| Liabilities and stockholders' equity | ||||||
| Current liabilities | ||||||
| Accounts payable and accrued expenses | $ | 1,903 | $ | 1,178 | ||
| Lease liabilities, current | 209 | 230 | ||||
| Other current liabilities | 347 | 360 | ||||
| Total current liabilities | 2,459 | 1,768 | ||||
| Lease liabilities, non-current | 16 | 19 | ||||
| Warrant liability | - | 1,372 | ||||
| Total liabilities | 2,475 | 3,159 | ||||
| Commitments and contingencies (Note 7) | - | - | ||||
| Stockholders' equity: | ||||||
| Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 1,106 and 13,765 shares issued and outstanding, at June 30, 2024 and December 31, 2023, respectively | - | - | ||||
| Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 1,721,900 and 889,668 shares issued and outstanding, at June 30, 2024 and December 31, 2023, respectively* | - | - | ||||
| Additional paid-in capital | 112,965 | 104,757 | ||||
| Accumulated other comprehensive loss | (1,422) | (1,578) | ||||
| Accumulated deficit | (106,955) | (95,066) | ||||
| Total stockholders' equity | 4,588 | 8,113 | ||||
| Total liabilities and stockholders' equity | $ | 7,063 | $ | 11,272 | ||
| * reflects a one-for-thirty-five (1:35) reverse stock split effected on September 21, 2023 | ||||||
| SMARTKEM, INC. | ||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||
| (Unaudited) | ||||||||||||
| (in thousands, except number of shares and per share data) | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| Revenue | $ | 40 | $ | 8 | $ | 40 | $ | 24 | ||||
| Cost of revenue | 32 | 6 | 32 | 22 | ||||||||
| Gross profit | 8 | 2 | 8 | 2 | ||||||||
| Other operating income | 236 | 169 | 438 | 438 | ||||||||
| Operating expenses | ||||||||||||
| Research and development | 1,158 | 1,257 | 2,434 | 2,536 | ||||||||
| Selling, general and administrative | 1,844 | 1,324 | 3,206 | 2,757 | ||||||||
| Loss on foreign currency transactions | 19 | (43) | 32 | 68 | ||||||||
| Total operating expenses | 3,021 | 2,538 | 5,672 | 5,361 | ||||||||
| Loss from operations | (2,777) | (2,367) | (5,226) | (4,921) | ||||||||
| Non-operating income/(expense) | ||||||||||||
| Gain/(loss) on foreign currency transactions | (243) | 533 | (249) | 1,035 | ||||||||
| Transaction costs allocable to warrants | - | (198) | - | (198) | ||||||||
| Change in fair value of the warrant liability | (81) | 3 | 672 | 3 | ||||||||
| Interest income | 3 | 2 | 9 | 6 | ||||||||
| Total non-operating income/(expense) | (321) | 340 | 432 | 846 | ||||||||
| Loss before income taxes | (3,098) | (2,027) | (4,794) | (4,075) | ||||||||
| Income tax expense | (1) | - | (1) | - | ||||||||
| Net loss | $ | (3,099) | $ | (2,027) | $ | (4,795) | $ | (4,075) | ||||
| Net loss | $ | (3,099) | $ | (2,027) | $ | (4,795) | $ | (4,075) | ||||
| Other comprehensive loss: | ||||||||||||
| Foreign currency translation | 174 | (517) | 156 | (973) | ||||||||
| Total comprehensive loss | $ | (2,925) | $ | (2,544) | $ | (4,639) | $ | (5,048) | ||||
| Common share data: | ||||||||||||
| Basic net loss per common share* | $ | (0.98) | $ | (1.82) | $ | (1.63) | $ | (4.18) | ||||
| Diluted net loss per common share* | $ | (0.98) | $ | (1.82) | $ | (4.04) | $ | (4.18) | ||||
| Dividend per common share | $ | - | $ | - | $ | (2.41) | ||||||